ADVERTISEMENT
For this second order to be effective, however, a penalty must be imposed in case the manufacturer fails to reach agreement with the foreign government or refuses to sell to Medicare at the price negotiated by that government. Such penalties are described in two bills sponsored by Democrats: either exclude the drug from Medicare coverage or authorize the manufacture of a generic version, despite any patent protection. These bills envision direct negotiation between Medicare and the manufacturer but would work equally well if negotiation were indirect, as we propose.
For decades, pharmaceutical companies have pursued twin strategies to deter imports. To scare Americans from importing, they have enlisted the government’s help in blurring the distinction between counterfeit drug sellers and licensed foreign pharmacies; and, to avoid the massive imports that wider price differentials would trigger, manufacturers have resisted pressure from foreign governments to negot
One out of two individuals who purchase long-term care insurance at age 65 will actually utilize their coverage according to data released by the American Association for Long-Term Care Insurance (AALTCI)."It's a 50-50 probability that someone getting long-term care insurance at age 65 will use their coverage and that's a
DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial
Table: IMU-838 Shows Acceleration of Time to Clinical Improvement
High-risk patients and patients aged over 65 years experienced a more substantial treatment benefit from IMU-838 than in the general patient population:
- The 75% probability
[5] to reach clinical improvement (based on investigator assessment) was accelerated by 3.8 days in IMU-838 treated high-risk patients
[6], as compared to placebo (FAS).
- The 75% probability
[5] to reach clinical improvement (based on investigator assessment) was accelerated by 4.8 days in IMU-838 treated elderly patients (65 years or older), as compared to placebo (FAS).
(2)
LONDON, Feb. 17, 2021 /PRNewswire/
Prenetics, the international health and diagnostics business which is leading testing for SARS-CoV-2 in centres across the world to open up ports of entry and other sectors, is pleased to announce the appointment of Dr Monique Andersson to its UK advisory board.
Dr Andersson, a Dutch and South African national, is a Consultant in Clinical Infection at the Oxford University NHS Foundation Trust in Oxford. She is an Honorary Senior Clinical Lecturer in Microbiology at the University of Oxford, visiting professor to Oxford Suzhou Centre for Advanced Research (OSCAR) and an Extraordinary Associate Professor of Medical Virology at the University of Stellenbosch, Cape Town, South Africa. Building on her experience as Director of the Microbiology Laboratory at the Oxford University Hospitals NHS Foundation Trust, she is now pioneering innovative diagnostics for infectious diseases, based at the OSCAR.
U.S. President Joe Biden has selected former Obama administration official Chiquita Brooks-LaSure to lead the Centers for Medicare and Medicaid Services (CMS), the Washington Post reported on Wednesday, citing three people with knowledge of the decision.